Brand Observation | One Company is Turning Custom Abutments into a New Growth Driver for Clinics

Foreword

In 2025, a policy intended to legitimize premium services triggered a counterintuitive market response.

The National Healthcare Security Administration released the "Guidelines for Establishing Oral Healthcare Service Price Projects," explicitly allowing personalized products to be priced autonomously. This was intended as a signal to unlock value, yet market prices plummeted: the average unit price of custom abutments dropped from three digits in 2023 to two digits in 2025.

The policy is "loosening," yet the market is "self-constraining." After dental implants shed their premium aura through volume-based procurement, the industry sought new value anchors. But why did a brutal self-compression arrive first?

Alberry—a third-party dental component brand launched by GF Medical Group in 2025—entered the arena at the height of the price war. It chose a divergent path: not defending low prices, but pricing for "certainty"—both the certainty of long-term product stability and the certainty of cost recovery for institutions.

In a market hijacked by extreme cost-cutting, how does this contrarian logic hold? When quality control becomes a cost and compliance becomes a burden, how does GF Medical make "certainty" both uphold clinical standards and unlock revenue opportunities for institutions?

The following:

On the Eve of Compliance: The Birth and Transformation of a "Gray" Track

To understand today's fierce competition, we must return to the market's origins. The scaled application of custom abutments in China began around 2012. At that time, an awkward reality was: many institutions could accept the procurement cost of implants but often hesitated before the prohibitive price tags of original manufacturer abutments.

Thus, the ingenuity of the processing factory market gave birth to a "pragmatic workaround": importing titanium blank stock and performing cutting domestically. This practice long operated in regulatory gray zones but indeed supported explosive market growth at one-third or even lower prices. According to senior industry estimates, its usage share once exceeded 70%. A vast "non-standard" market quietly formed, driven jointly by clinical demand and cost pressure.

The turning point came in 2019.

As medical device regulatory systems tightened, compliance became an irreversible trend. Almost simultaneously, GF Medical Group obtained China's first Class III medical device registration certificate for custom abutments.

This "license" came at the perfect moment. On one hand, numerous processing factories relying on non-compliant channels faced survival pressure; on the other, whether transitioning factories or international brands seeking localized production (such as Straumann), there emerged urgent demand for qualified and reliable suppliers.

GF Medical seized this opportunity to undertake substantial OEM orders from major manufacturers and, through years of contract manufacturing, accumulated two critical assets: official interface data authorizations from multiple mainstream implant systems, and a precision manufacturing and quality control system meeting stringent international standards.

Caption: GF Medical Group production workshop

Behind this capability lies over 30 years of precision manufacturing accumulation. From starting as a tool factory in 1992, to introducing imported equipment from Switzerland and Japan in 2011, to establishing cooperation with nearly 300 dental labs and multiple hospitals nationwide—this network density enabled GF Medical to make a counterintuitive judgment in 2025.

As of 2025, GF Medical has established solid partnerships with nearly 300 dental labs and multiple public and private dental hospitals nationwide. This network density is market validation of long-term reliability and the confidence behind Alberry brand's contrarian pricing.

As the entire industry descended into price wars, GF Medical saw something different: amid the wave of universally compressing quality control for survival, scenarios with rigid demand for "certainty" and "long-term stability" became an overlooked value blind spot.

When "Cost-Cutting" Slides into "Gamble": How Price Wars Devour Quality Control Baselines

However, after volume-based procurement for dental implants fully landed, profit margins across the supply chain were forcibly reshaped. Custom abutments, which should have carried technical value, rapidly became the most brutal battlefield of price wars.

The cost structure of an abutment is actually quite clear: medical-grade titanium alloy materials, precision cutting processing losses, and necessary quality testing and traceability. When terminal prices were compressed from three digits to two, material costs could hardly be further reduced, so all pressure shifted to processing and quality control.

Thus, the market began exhibiting various "survival strategies."

The most typical is "certificate outsourcing": licensed enterprises outsource actual production to hardware factories without medical device qualifications, only handling branded sales themselves. This exchanges for asset-light operations but sacrifices product consistency. According to the new version of "Quality Management Standards for Medical Device Production" released by the National Medical Products Administration in November 2025, such delegated production practices will face stricter scrutiny after November 2026.

Related Reading: Medical Device Production Regulation Countdown: 12 Months Left for Oral Device Companies

More covert risks hide in materials. Substituting industrial-grade or non-standard materials for medical-grade titanium alloy can directly reduce raw material costs. But the fatigue strength and corrosion resistance of such materials often fail to meet the harsh oral long-term implantation environment, planting hidden dangers for future loosening, thread stripping, or even fracture.

Even in-house manufacturers, under extreme cost pressure, may fall into dilemmas: equipment precision inevitably declines after long-term use, causing critical tolerance to lose control. But replacing high-precision equipment means heavy reinvestment, leaving some enterprises struggling between "operating while broken" and "abandoning orders."

The commonality of the above "survival strategies" is: postponed risk. Problems are perfectly hidden when products leave the factory but gradually expose 6 months to 2 years after implantation in patients' mouths. A regional leading chain dental practice head calculated an account: in 2024, after-sales costs due to abutment issues (including dentist rework, customer complaints, brand damage) significantly eroded the profit of implant restoration business.

This reveals a paradox: procurement costs seemingly saved are often repaid double in after-sales; while compliant products that can be billed separately and reduce rework risks may actually create healthier profit structures for institutions.

Thus, as the implant volume-based procurement era expanded, discussions on "abutment fracture" on social platforms also became prominent:

*Source: A social media app

Money saved on procurement orders is often repaid double in after-sales—while compliant products that can be billed separately and reduce rework risks are reducing operational pressure for institutions.

Going Against the Current: How is the "Safety Margin" Constructed?

When low-price competition forces the industry to postpone risks, Alberry's approach essentially intercepts the long-term complication risks that clinical dentists most worry about at the factory end as early as possible. The logic of this system is clear: trade verifiable precision and traceability for predictable long-term stability.

Interception starts with connection precision. Based on official interface data authorization, combined with Willemin-Macodel 5-axis machining center achieving ±0.05mm precision, errors are reduced to one-third of industry standards (industry standard ±0.15mm), with the primary goal of physically reducing initial micromotion and screw loosening caused by poor fit—the most common cause of clinical rework. But precision is just the starting point.

A deeper consideration lies in craftsmanship. Adopting "slow processing" and multiple precision refinements enhances surface finish and edge sealing. A smooth, precise restoration edge significantly reduces plaque attachment, lowering peri-implantitis risk. This determines survival rates over ten or even twenty years.

*Source: GoodNews DataLab

On the material front, insisting on using German Sapu TC4 ELI medical-grade titanium alloy—the medical gold standard in the global implant industry, with extremely low interstitial elements (ELI grade) achieving high fatigue strength and biocompatibility, specifically designed for long-term load-bearing implantation. Combined with complete testing reports, it ensures material fatigue resistance and corrosion resistance in the oral environment from the source, avoiding long-term fracture risks.

Most critically is traceability. The full-process UDI traceability system is like a detailed product medical record. When clinical questions arise, it helps dentists quickly rule out product batch issues, focusing troubleshooting on other links, greatly saving time on doctor-patient communication and problem tracing.

Source: GF Medical Group

The credibility of this system comes from over one million custom abutments validated clinically (data as of June 2022). This figure means: the manufacturing platform Alberry relies on has undergone sufficient long-cycle testing in real oral environments. Meanwhile, People's Insurance Company of China (PICC) underwrites its product quality, converting the manufacturing end's "certainty commitment" into claimable insurance liability—this stance of "daring to have third-party backing" is uncommon in a market dominated by price wars.

This verifiability extends not only to clinical ends but also to another key institutional operation link—billing compliance. Complete UDI and medical insurance coding allow Alberry personalized restoration solutions to be listed as independent items on patient bills. Compared to consumables that cannot be billed separately and must be bundled in "implant restoration," it provides institutions with clear cost pricing basis—no need to squeeze or hide in bundled pricing.

Therefore, for clinical ends, the commercial logic of this system can be translated into a more pragmatic question: Can it reduce my full-cycle clinical management costs?

The market's answer presents clear stratification logic across different decision scenarios.

In public hospital systems, this system's value translates into another rigid need: audit safety. GoodNews learned that public hospital technical labs have approved budgets several times normal for their bridge frameworks, essentially purchasing a fully verifiable system that can withstand rigorous scrutiny—paying a premium for "audit risk certainty."

For large processing factories like KTJ Medical and YZJ Dental Lab serving multiple hospitals, the selection logic is more direct: supply chain risk control. Choosing suppliers with complete qualifications and traceability capabilities means establishing clear "responsibility firewalls," transcending price-based procurement to become a rigid demand for managing their own quality risks.

In high-end consumer markets, "certainty" itself has become a sellable core commodity. Suihua Dental, a leading chain brand in the Greater Bay Area, shows that over half of semi-arch and full-arch patients in the past month actively chose Alberry. For clinics, this provides more diverse service options for patients; for patients, the explicit promise of "long-term stability" is value in itself.

Market stratification clearly outlines a new value curve. Supporting Alberry's pricing power on this curve is GF Medical's systematic capabilities accumulated over the long term as a manufacturing entity—in 2025, the company was selected as a national-level "Specialized, Refined, Differential and Innovative" Little Giant, and its R&D project with Shanghai Ninth People's Hospital and University of Science and Technology of China won first prize for Shanghai Technological Invention.

Source: GF Medical Group

These dual endorsements from industry and academia jointly confirm one point: products that can win pricing power amid market stratification often have companies' long-term, silent investments in precision manufacturing and systematic innovation behind them.

This perhaps also reveals an ongoing industry value reconstruction: one part of demand will always anchor to the lowest procurement price, while another part—whether due to compliance mandates, risk calculations, or consumer trust—has begun to seriously re-price for "certainty." Price wars define survival baselines, while different approaches to risk disposal are leading enterprises toward vastly different futures.

Afterword

Looking back at Alberry's brand positioning, it resembles an industry experiment in "deep professionalism." It chose not to cover all price segments but to do something "slow" in a field generally considered only capable of price competition: building verifiable reliability and traceability systems to accumulate trust assets requiring time to settle.

When price wars can flatten superficial competitive differences in the short term, capabilities that cannot be quickly replicated—such as authorization-based data foundations, precision manufacturing processes, complete traceability chains—may instead construct more enduring differentiation. This differentiation manifests not only in long-term clinical stability but also in compliant revenue space created for institutions—when quality becomes verifiable value, pricing power naturally returns.

Admittedly, the current price war's clamor remains deafening. But beneath the clamor, another rhythm based on professional depth and long-term trust has begun to quietly pulse. This is not the only answer, but it suggests a possibility: when most bow their heads seeking survival crevices in red oceans, some will look up to construct their own altitude.

This is both a business choice and the industry's self-examination amid value fracture.